The future of genetic and biomarker studies in neonatal disorders looks promising, with ongoing research focusing on discovering new biomarkers and genetic mutations. Advances in technology, such as CRISPR for gene editing and more sensitive mass spectrometry techniques, are likely to play a crucial role. Additionally, integrating data from multiple sources, including genomic, proteomic, and clinical data, will enhance our understanding and management of neonatal disorders.
